Actively Recruiting
China Early Esophageal Cancer Cohort
Led by Changhai Hospital · Updated on 2024-07-23
1000
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
C
Changhai Hospital
Lead Sponsor
L
Lianshui People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
With the development of endoscopy, more and more patients with superficial esophageal squamous cell carcinoma (ESCC) receive endoscopic resection rather than traditional surgery. However, there is still no complete consensus on the risk factors for lymph node metastasis (LNM) and recurrence of ESCC after endoscopic resection. The existing curative resection criteria are strict to a certain extent, and a considerable number of patients are overtreated according to the current standard of additional treatment. Thus, we aim to conduct a multi-center retrospective and prospective study to construct a large cohort of ESCC based on the previously established multi-center collaborative research network and clinical big data, analyze the risk factors of LNM and recurrence in patients with early esophageal squamous cell carcinoma after ESD, establish an accurate and simple risk prediction model, and evaluate the discrimination efficiency of this model.
CONDITIONS
Official Title
China Early Esophageal Cancer Cohort
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 18 to 85 years
- Early (superficial) esophageal squamous cell carcinoma treated with endoscopic submucosal dissection (ESD)
- Pathological stage after ESD is pT1a or pT1b
- Effective follow-up time after ESD of at least 3 years or occurrence of recurrence or lymph node metastasis during follow-up
You will not qualify if you...
- Prior esophageal chemoradiotherapy or esophageal surgery before ESD
- History of carcinoma, early carcinoma, adenoma, or other benign and malignant tumors of the stomach or duodenum
- Incomplete pathological data after ESD
- Presence of malignant tumors in other organs
- Use of fragmented endoscopic mucosal resection (EMR), multi-loop mucosal resection (MBM), or other non-monolithic endoscopic resection techniques
- Development of new squamous cell carcinoma in other parts of the esophagus during follow-up (metachronous carcinoma)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Changhai Hospital
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
Research Team
L
Luowei Wang, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here